Chelating intracellular calcium reduces fibroblast senescence and eases lung fibrosis
Treating cells and an in vivo fibrosis model with a calcium chelator delayed senescence markers, reduced collagen buildup, and dampened inflammatory secretions.
Biochimica et biophysica acta. General subjects · Xu J et al. · Paper published 30 Sep 2026
In experiments using cultured fibroblasts and an in vivo animal model, researchers examined how intracellular calcium changes during cellular senescence and pulmonary fibrosis. They measured free calcium levels during senescence and observed a significant increase. Chelating this intracellular calcium buildup delayed the elevation of calcium, lowered reactive oxygen species accumulation, decreased DNA damage, and slowed fibroblast senescence. In the animal model, intraperitoneal administration of the calcium chelator BAPTA-AM markedly alleviated pulmonary fibrosis. The treatment reduced body weight loss, inflammatory cell infiltration, and collagen deposition, while lowering senescence and fibrosis markers. Transcriptomic analysis of fibrotic lung tissues confirmed that BAPTA-AM treatment also significantly suppressed the senescence-associated secretory phenotype.
Why it matters
Intracellular calcium signaling is a known feature of cellular senescence, but its operational role in fibrotic lung pathology has been unclear. These findings show that directly curbing calcium accumulation can restrain senescence markers and lessen tissue remodeling in age-associated diseases.
Caveats
The findings are limited to cell culture and an animal model, meaning effects may differ in clinical human settings. The abstract also does not evaluate long-term safety, optimal dosing, or whether the treatment can reverse advanced fibrosis.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Limiting the intracellular calcium accumulation alleviates fibroblast senescence and pulmonary fibrosis
Xu J, Yang J, Sun W et al.
Biochimica et biophysica acta. General subjects · 30 Sep 2026 · Peer-reviewed
- Relevance
- Core geroscience
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.